- Home
- AMRN vs DHF Comparison
AMRN vs DHF Comparison
Compare AMRN & DHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$15.31
Company Overview
Basic Information| Metric | AMRN | DHF |
|---|---|---|
| Founded | 1989 | 1998 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.8M | 185.7M |
| IPO Year | 1993 | N/A |
Fundamental Metrics
Financial Performance| Metric | AMRN | DHF |
|---|---|---|
| Price | $15.31 | $2.52 |
| Analyst Decision | Strong Sell | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | 101.9K | ★ 451.1K |
| Earning Date | 03-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.65% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $226,733,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.08 | $2.06 |
| 52 Week High | $20.90 | $2.39 |
Technical Indicators
Market Signals| Indicator | AMRN | DHF |
|---|---|---|
| Relative Strength Index (RSI) | 54.54 | 52.75 |
| Support Level | $14.50 | $2.47 |
| Resistance Level | $16.80 | $2.53 |
| Average True Range (ATR) | 0.83 | 0.02 |
| MACD | 0.16 | 0.00 |
| Stochastic Oscillator | 59.37 | 71.43 |
Price Performance
Historical Comparison AMRN
DHF
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. The fund invests predominantly in fixed-income securities of below-investment-grade credit quality.